

61. Progress in clinical trials for TB treatment: 2015

**THE 46TH UNION
WORLD CONFERENCE
ON LUNG HEALTH**

CAPE TOWN, SOUTH AFRICA
2-6 DECEMBER 2015

Sunday, 06 December 2015, 13:30 - 15:00

Roof Terrace

Type of session	Symposium
Track	Drug-sensitive TB care and treatment, including trials
Track2 (optional)	Drug-resistant TB care and treatment, including trials
Description	The current drug development pipeline holds the largest number of new TB drugs ever. Multiple groups are involved in the late stages of drug development, including members of the academic, governmental, non-profit and commercial pharmaceutical sectors. These groups support or implement trials that seek to re-purpose or optimise existing drugs, as well as develop novel compounds and regimens with the aim of simplifying or shortening TB treatment. This session will present emerging data from leading groups.
Target audience	<ol style="list-style-type: none"> 1. TB clinicians and healthcare workers, TB programme managers, drug developers 2. TB researchers, pulmonary and infectious disease clinicians, pharmacologists 3. TB programme staff, epidemiologists and others involved in clinical trials
Objectives	<ol style="list-style-type: none"> 1. Present recent advances in phase 2 and phase 3 trials of new TB drugs and regimens for drug-sensitive TB 2. Discuss the challenges confronting development of new TB therapies through sharing of practical experiences 3. Inform the target audience concerning safety of drugs 4. Assist the target audience in considering the utility of new or imminently available TB drugs and regimens
Keywords	Drugs; treatment; trials
Coordinator(s)	Andrew Vernon (USA), Sarita Shah (USA)
Chair(s)	Richard Menzies (Canada), Neil Martinson (South Africa)
Presentations	<p>13:30 - 13:40 High-dose rifampicin: issues in efficacy and safety Martin Boeree (Netherlands)</p> <p>13:45 - 13:55 High-dose rifapentine: preparation and design of a four-month regimen trial Susan Dorman (USA)</p> <p>14:00 - 14:10 The evolving trials and strategy of the TB Alliance Carl Mendel (USA)</p> <p>14:15 - 14:25 Tuberculosis trials from the AIDS Clinical Trials Group Susan Swindells (USA), Richard Hafner (USA)</p> <p>14:30 - 14:40 MDR-TB: multiple trials moving forward Keertan Dheda (South Africa)</p> <p>14:45 - 15:00 Discussion</p>